Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature
| العنوان: | Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature |
|---|---|
| المؤلفون: | Marloes Swets, Cristina Graham Martinez, Shannon van Vliet, Arjan van Tilburg, Hans Gelderblom, Corrie A M Marijnen, Cornelis J H van de Velde, Iris D Nagtegaal |
| المصدر: | Histopathology, 81(3), 352-362. WILEY Histopathology, 81, 3, pp. 352-362 Histopathology, 81, 352-362 |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Histology, Rectal Neoplasms, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Humans, microsatellite instability, Prospective Studies, General Medicine, prognosis, Colorectal Neoplasms, rectal cancer, Neoplasm Staging, Randomized Controlled Trials as Topic, Pathology and Forensic Medicine |
| الوصف: | Contains fulltext : 283497.pdf (Publisher’s version ) (Open Access) AIM: Currently, compelling evidence illustrates the significance of determining microsatellite instability (MSI) in colorectal cancer (CRC). The association of MSI with proximal CRC is well established, however, its implications in patients with rectal cancer remain undefined. We therefore aimed to determine the role of MSI with respect to incidence and outcome in patients with rectal cancer. METHODS AND RESULTS: For this we examined patients from two prospective phase III trials: TME trial and PROCTOR-SCRIPT trial (n = 1250). In addition, we performed a literature review to evaluate the overall prevalence, the effect on survival and the response to neo-adjuvant treatment in patients with MSI rectal cancer compared with microsatellite stable (MSS) rectal cancer. Our TME and PROCTOR-SCRIPT cohort showed no differences in terms of overall survival (OS) (hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.69-1.47) and disease-free survival (DFS) (HR 1.00, 95% CI 0.68-1.45) in patients with MSI compared to MSS rectal cancer. The total number of MSI cases in all included studies (including our own) was 1220 (out of 16,526 rectal cancer patients), with an overall prevalence of 6.7% (standard error 1.19%). Both for OS as for DFS there was no impact of MSI status on prognosis (HR 1.00, 95% CI 0.77-1.29 and HR 0.86, 95% CI 0.60-1.22, respectively). The risk ratio (RR) for downstaging and pathological complete response showed also no impact of MSI status (RR 1.15, 95% CI 0.86-1.55 and RR 0.81, 95% CI 0.54-1.22, respectively). CONCLUSION: Rectal cancer patients with MSI form a distinct and rare subcategory, however, there is no prognostic effect of MSI in rectal cancer patients. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0309-0167 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40bee4bebb2ac8e1aac80add14115c75 https://hdl.handle.net/1887/3563464 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....40bee4bebb2ac8e1aac80add14115c75 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 03090167 |
|---|